Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
DMB-3115 (ustekinumab) is a proposed biosimilar to Stelara being used for the treatment of plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: DMB-3115
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023
Details:
DMB-3115 (ustekinumab) and Stelara demonstrated therapeutic equivalence when looking at percent change from baseline in PASI (Psoriasis Area and Severity Index) at Week 8 and Week 12.
Lead Product(s): Ustekinumab
Therapeutic Area: Dermatology Product Name: DMB-3115
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.
Lead Product(s): Darbepoetin alfa
Therapeutic Area: Hematology Product Name: DA-3880
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Polifarma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2022
Details:
Under the license agreement, NeuroBo has obtained an exclusive license to develop and commercialize DA-1241 (a novel GPR119 agonist) and DA-1726, which are currently being evaluated for the treatment of nonalcoholic steatohepatitis (NASH), obesity and type 2 diabetes.
Lead Product(s): DA-1241
Therapeutic Area: Endocrinology Product Name: DA-1241
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuroBo Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 08, 2022
Details:
DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the release of key gut peptides GLP-1, GIP and PYY, which, in turn, play an important role in glucose metabolism, lipid metabolism and weight loss.
Lead Product(s): DA-1241
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: DA-1241
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: NeuroBo Pharmaceuticals
Deal Size: $37.0 million Upfront Cash: $22.0 million
Deal Type: Licensing Agreement September 15, 2022
Details:
As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global rights for further development and commercialization for different compounds series developed during the collaboration.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Recipient: Beactica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination September 06, 2022
Details:
STP0404 also demonstrated consistent pharmacokinetics at various dose levels showing drug exposure increased less-proportionally with dose, and presented an elimination half-life can support once daily dosing regimen.
Lead Product(s): STP0404
Therapeutic Area: Infections and Infectious Diseases Product Name: STP0404
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022